Claritev Q2 Revenue Beats, but Material Weakness and DOJ Probe Linger
CTEV has more than doubled off its 52-week low of $11.5 on elevated volume (2.2× avg).
Summary
Claritev's Q2 2026 revenue and adjusted EBITDA beat expectations, but the 10-Q discloses an unremediated material weakness, an ongoing DOJ civil probe, and high client concentration.
Key Events · Earnings and Guidance · CTEV
-
Q2 Revenue and EBITDA Beat
Revenue rose 6.6% YoY to $257.5M; adjusted EBITDA reached $155.8M, exceeding consensus estimates.
-
Material Weakness Unremediated
IT general control deficiencies remain unremediated as of June 30, 2026, causing disclosure controls to be ineffective.
-
DOJ Civil Probe Ongoing
The DOJ closed its criminal antitrust investigation but issued a civil investigative demand on May 19, 2026; the outcome and potential penalties are uncertain.
-
High Client Concentration
One client accounted for 35% of Q2 2026 revenue, posing a material risk if the relationship is lost.
Analysis · CTEV · Trade & Services
Claritev posted a solid Q2 with revenue up 6.6% to $257.5M and adjusted EBITDA of $155.8M, beating expectations. However, the 10-Q reveals that a previously disclosed material weakness in IT controls remains unremediated, rendering disclosure controls ineffective. The DOJ civil investigation is ongoing, and the company disclosed that one client represents 35% of revenue — a significant concentration risk. Two executives also adopted 10b5-1 trading plans, signaling potential future insider sales.
At the time of this filing, CTEV was trading at $32.59 on NYSE in the Trade & Services sector, with a market capitalization of approximately $555.6M. The 52-week trading range was $11.50 to $74.07. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.